BLCO · Bausch & Lomb Corp
$16.76
+0.41 (+2.51%)
At close · Aug 7
Market Cap
$5.84B
Shares
357.17M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$16.35
Open$16.81
Day$16.31–16.81
52W$13.53–18.92
Avg vol 30d422K
Short int3.8M · 1.1% float · 10.3d
Short vol37%
Last earningsJul 29, 2026
DataMay 2022–Aug 2026
Filing10-Q · Jul 29
Up next
Next earnings call
Oct 28, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 29, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Poor
Quant / Vol
Moderate
Market backdrop
VIX 15.2 · calm
Equity put/call 0.60
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−0%
below
Price vs 50-day avg
+2%
above
RSI (14)
50
neutral
MACD trend
Positive
52-week position
52%
mid-range
Momentum
relative strength
1-month return
−2%
trailing
6-month return
−2%
trailing
YTD return
−4%
this year
Relative strength
−15%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $16 › 200d $16 — 200d above 50d
Institutional flow
Accumulating
23 of 96 funds reported for Jun 30 · net +206.8K sh shares · +4 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.06% of float · ▼ -4.6% MoM · 10.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
96 holders — mid 3-yr range
Squeeze score
51
elevated · 0–100
Fundamentals
Revenue growth
+6%
Y/Y
EPS growth
−13%
Y/Y
Free cash flow
$-66.0M
Balance sheet
$4.7B
net debt
Quant / Vol
risk profile
Volatility
30%
annualized · 1-yr
Max drawdown
−20%
past year
ATR
3.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Apr 29, 2026
Full-Year Revenue
· Full-Year 2026
Initiated
$5.42B – $5.52B
prior FY $5.1B
midpoint +7.2% Y/Y
Full-Year Revenue Foreign Exchange Tailwinds
· Full-Year 2026
Initiated
$50M
Guided vs delivered
· last 2 settled
Full year revenue
full year
guided $5.05B – $5.15B
$5.1B
In line
Full year revenue
full year 2024
guided $4.73B – $4.83B
$4.79B
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−0%
Neutral
Price vs 50-day avg
+2%
Bullish
RSI (14)
50
Neutral
MACD trend
Positive
Bullish
52-week position
52%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $16 › 200d $16 — 200d above 50d
Institutional flow
Accumulating
23 of 96 funds reported for Jun 30 · net +206.8K sh shares · +4 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.06% of float · ▼ -4.6% MoM · 10.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
96 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $14
Now $16 · 52%
52-wk high $19
vs 200-day avg 0%
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA (non-GAAP) non-GAAP | $241M | the second quarter of 2026 | — |
|
|
|||
| Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP) non-GAAP | $246M | the second quarter of 2026 | — |
|
|
|||
| total dry eye portfolio revenue | $0.3B | FY2026 Q2 | +15.4% |
|
|
|||
| Adjusted net income attributable to Bausch + Lomb Corporation (non-GAAP) non-GAAP | $152M | the full year of 2025 | — |
| Cash flow from operations | $283M | the full year of 2025 | — |
| MIEBO sales | $112M | the fourth quarter | — |
| premium IOL reported revenue growth | 20% | the fourth quarter of 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BLCO
this stock
Bausch & Lomb Corp
|
$5.84B | -4.3% | +6.5% | — | 1.1% |
|
ISRG
Intuitive Surgical Inc
|
$132.02B | -34.0% | +20.5% | 42.9 | 1.9% |
|
BDX
Becton Dickinson & Co
|
$48.23B | +17.6% | +8.2% | 88.5 | 3.8% |
|
MDLN
Medline Inc.
|
$45.37B | -17.8% | +11.5% | — | 2.2% |
|
ALC
Alcon Inc
|
$33.91B | -11.3% | +10.5% | — | 2.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BLCO | -3.8% | -2.3% | -2.3% | -3.3% | -4.3% |
| SPY | +3.6% | +2.2% | +12.8% | +2.9% | +12.7% |
| vs SPY | -7.4% | -4.5% | -15.1% | -6.2% | -17.0% |
Key facts
CIK
1860742
CUSIP
071705107
13F (30d)
20 filings
20 filers
Visit website
Investor relations